HIGHLIGHTS
- who: Stephanie L. Alden et al. from the Sapienza University of Rome, Italy have published the research work: Post-operative ctDNA monitoring in stage I colon cancer: A case report, in the Journal: (JOURNAL)
SUMMARY
While initial therapy for non-metastatic, resectable colon cancer is well-established, adjuvant chemotherapy is not recommended for those with stage I and low-risk stage II disease. While studies evaluating the use of ctDNA to guide treatment have focused on the potential to refine patient selection for adjuvant chemotherapy in stage II colon cancer and potentially deescalate . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.